Has Asiminib been included in the scope of medical insurance reimbursement?

Asciminib (Asciminib) is an innovative targeted drug used to treat chronic myelogenous leukemia (CML). It is a specific ABLInhibitors, whose mechanisms are different from traditional tyrosine kinase inhibitors (TKIs), have significant effects on some patients who are resistant or intolerant to other TKIs. At present, the drug has not been approved for marketing in China, and therefore it is not included in the scope of national medical insurance reimbursement. Patients cannot purchase it directly in domestic hospital pharmacies.

Since it is not available domestically, patients who need to use acemini can only purchase the drug through overseas channels. There are currently two main versions on the market: one is the European version of the original drug, and the other is a generic drug produced by a Lao pharmaceutical factory. Original medicines are very expensive, with each box selling for tens of thousands of yuan, which is a heavy financial burden for many families. Despite this, original drugs have more comprehensive guarantees in terms of efficacy, safety and clinical research data.

In comparison, the generic drug of Asiminib produced in Laos is affordable, with each box of about more than 4,000 yuan, which is cost-effective, and its drug ingredients are basically the same as the original drug, which can provide treatment opportunities for patients with greater financial pressure. Although the use of generic drugs has certain legal and regulatory issues in some areas, it is still a realistic and feasible option for patients who urgently need medication.

In short, Acemini is not currently on the market in my country, nor has it entered the medical insurance system. Patients need to obtain it through regular overseas drug channels. Considering the obvious price differences between drugs, patients should fully weigh their financial ability and treatment needs when choosing, and it is recommended to use drugs rationally under the guidance of a doctor to ensure efficacy and safety.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib